Literature DB >> 16050794

Angiotensin-(1-7) and its receptor as a potential targets for new cardiovascular drugs.

Robson A S Santos1, Anderson J Ferreira, Sérgio V B Pinheiro, Walkyria O Sampaio, Rhian Touyz, Maria José Campagnole-Santos.   

Abstract

The identification of novel biochemical components of the renin-angiotensin system (RAS) has added a further layer of complexity to the classical concept of this cardiovascular regulatory system. It is now clear that there is a counter-regulatory arm within the RAS that is mainly formed by the angiotensin-converting enzyme 2-angiotensin (1-7)-receptor Mas axis. The functions of this axis are often opposite to those attributed to the major component of the RAS, angiotensin II. This review will highlight the current knowledge concerning the cardiovascular effects of angiotensin-(1-7) through a direct interaction with its receptor Mas or through an indirect interplay with the kallikrein-kinin system. In addition, there will be a discussion of its role in the beneficial effects of angiotensin-converting enzyme inhibitors and angio-tensin receptor type 1 (AT1) antagonists, and the potential of this peptide and its receptor as a novel targets for new cardiovascular drugs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16050794     DOI: 10.1517/13543784.14.8.1019

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN: 1354-3784            Impact factor:   6.206


  28 in total

Review 1.  Role of ACE2 in diastolic and systolic heart failure.

Authors:  Wang Wang; Sreedhar Bodiga; Subhash K Das; Jennifer Lo; Vaibhav Patel; Gavin Y Oudit
Journal:  Heart Fail Rev       Date:  2012-09       Impact factor: 4.214

Review 2.  Angiotensin-converting enzymes and drug discovery in cardiovascular diseases.

Authors:  Lijun Shi; Caiping Mao; Zhice Xu; Lubo Zhang
Journal:  Drug Discov Today       Date:  2010-02-17       Impact factor: 7.851

Review 3.  ACE2: more of Ang-(1-7) or less Ang II?

Authors:  Carlos M Ferrario
Journal:  Curr Opin Nephrol Hypertens       Date:  2011-01       Impact factor: 2.894

Review 4.  Recombinant human angiotensin-converting enzyme 2 as a new renin-angiotensin system peptidase for heart failure therapy.

Authors:  Gavin Y Oudit; Josef M Penninger
Journal:  Curr Heart Fail Rep       Date:  2011-09

5.  AVE 0991, a non-peptide mimic of angiotensin-(1-7) effects, attenuates pulmonary remodelling in a model of chronic asthma.

Authors:  M G Rodrigues-Machado; G S Magalhães; J A Cardoso; L M Kangussu; A Murari; M V Caliari; M L Oliveira; D C Cara; M L M Noviello; F D Marques; J M Pereira; R Q Lautner; R A S Santos; M J Campagnole-Santos
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

6.  Angiotensin-(1-7) increases neuronal potassium current via a nitric oxide-dependent mechanism.

Authors:  Rui-Fang Yang; Jing-Xiang Yin; Yu-Long Li; Matthew C Zimmerman; Harold D Schultz
Journal:  Am J Physiol Cell Physiol       Date:  2010-10-27       Impact factor: 4.249

7.  Angiotensin converting enzyme 2/Ang-(1-7)/mas axis protects brain from ischemic injury with a tendency of age-dependence.

Authors:  Jiao-Lin Zheng; Guang-Ze Li; Shu-Zhen Chen; Jin-Ju Wang; James E Olson; Hui-Jing Xia; Eric Lazartigues; Yu-Lan Zhu; Yan-Fang Chen
Journal:  CNS Neurosci Ther       Date:  2014-03-02       Impact factor: 5.243

8.  Diminazene attenuates pulmonary hypertension and improves angiogenic progenitor cell functions in experimental models.

Authors:  Vinayak Shenoy; Altin Gjymishka; Yagna P Jarajapu; Yanfei Qi; Aqeela Afzal; Katya Rigatto; Anderson J Ferreira; Rodrigo A Fraga-Silva; Patrick Kearns; Jane Yellowlees Douglas; Deepmala Agarwal; Kamal K Mubarak; Chastity Bradford; William R Kennedy; Joo Y Jun; Anandharajan Rathinasabapathy; Erin Bruce; Dipankar Gupta; Arturo J Cardounel; J Mocco; Jawaharlal M Patel; Joseph Francis; Maria B Grant; Michael J Katovich; Mohan K Raizada
Journal:  Am J Respir Crit Care Med       Date:  2013-01-31       Impact factor: 21.405

Review 9.  Development of fetal brain renin-angiotensin system and hypertension programmed in fetal origins.

Authors:  Caiping Mao; Lijun Shi; Feichao Xu; Lubo Zhang; Zhice Xu
Journal:  Prog Neurobiol       Date:  2009-01-24       Impact factor: 11.685

Review 10.  Are we poised to target ACE2 for the next generation of antihypertensives?

Authors:  Anderson J Ferreira; Mohan K Raizada
Journal:  J Mol Med (Berl)       Date:  2008-05-01       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.